| Natalie S Justicz, | |
|
1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 | |
| (734) 936-4000 | |
| Not Available |
| Full Name | Natalie S Justicz |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 9 Years |
| Location | 1500 E Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144637893 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 4301501761 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Maryland Medical Center | Baltimore, MD | Hospital |
| University Of Md Medical Center Midtown Campus | Baltimore, MD | Hospital |
| University Of Md Baltimore Washington Medical Center | Glen burnie, MD | Hospital |
| Saint Agnes Hospital | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. Agnes Healthcare, Inc. | 9830092733 | 237 |
| Univ Of Maryland Otorhinolaryngology Head And Neck Surgery Pa | 8820026974 | 16 |
News Archive
Namukolo Covic, senior research coordinator at the International Food Policy Research Institute and one of the authors of the article, said such a mechanism was important for holding not just governments, but commercial enterprises to account.
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.
Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune system - a weakness that in principle could be corrected with a HER2-targeted vaccine - according to a new study from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 3 days ago
| Entity Name | St. Agnes Healthcare, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144250176 PECOS PAC ID: 9830092733 Enrollment ID: O20040128001146 |
News Archive
Namukolo Covic, senior research coordinator at the International Food Policy Research Institute and one of the authors of the article, said such a mechanism was important for holding not just governments, but commercial enterprises to account.
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.
Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune system - a weakness that in principle could be corrected with a HER2-targeted vaccine - according to a new study from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 3 days ago
| Entity Name | Univ Of Maryland Otorhinolaryngology Head & Neck Surgery Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104832948 PECOS PAC ID: 8820026974 Enrollment ID: O20050729000661 |
News Archive
Namukolo Covic, senior research coordinator at the International Food Policy Research Institute and one of the authors of the article, said such a mechanism was important for holding not just governments, but commercial enterprises to account.
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.
Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune system - a weakness that in principle could be corrected with a HER2-targeted vaccine - according to a new study from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Natalie S Justicz, 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Natalie S Justicz, 1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 Ph: (734) 936-4000 |
News Archive
Namukolo Covic, senior research coordinator at the International Food Policy Research Institute and one of the authors of the article, said such a mechanism was important for holding not just governments, but commercial enterprises to account.
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.
Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune system - a weakness that in principle could be corrected with a HER2-targeted vaccine - according to a new study from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 3 days ago
Jeffrey John Stanley, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Erin Lynn Mckean, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Susan L Garetz, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1500 East Medical Center Dr, 2nd Floor Taubman Cter Recp G, Ann Arbor, MI 48109 Phone: 734-936-5730 | |
Jeffrey Scott Moyer, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Amarbir Singh Gill, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Robert Harris Gilman, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105 Phone: 734-998-6022 Fax: 734-998-9139 |